Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

B-Cell CLL/lymphoma 7A (BCL7A) Peptid

BCL7A Reaktivität: Säugetier Wirt: Synthetic BP, WB, IHC
Produktnummer ABIN937090
  • Target Alle BCL7A Produkte
    BCL7A (B-Cell CLL/lymphoma 7A (BCL7A))
    Protein-Typ
    Synthetic
    Spezies
    Säugetier
    Quelle
    • 5
    Synthetic
    Applikation
    Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
    Sequenz
    CGSEVTTPEN SSSPGMMDMH DDNSNQSSIA DASPIKQENS SNSSPAPEPN
    Produktmerkmale
    A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7 A antibody,
    Alternative Names: BCL7A control peptide, BCL7A antibody Blocking Peptide, Anti-BCL7A Blocking Peptide, B-Cell Cll/Lymphoma 7A Blocking Peptide, BCL7 Blocking Peptide, BCL7A, BCLA-7, BCLA 7, BCLA-7 Blocking Peptide, BCLA 7 Blocking Peptide
  • Applikationshinweise
    Optimal conditions should be determined by the investigator
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
    Buffer
    PBS
    Handhabung
    Avoid repeated freeze/thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Store at -20 °C long term.
  • Target
    BCL7A (B-Cell CLL/lymphoma 7A (BCL7A))
    Hintergrund
    This gene is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line. As a result of the gene translocation, the N-terminal region of the gene product is disrupted, which is thought to be related to the pathogenesis of a subset of high-grade B cell non-Hodgkin lymphoma. The N-terminal segment involved in the translocation includes the region that shares a strong sequence similarity with those of BCL7B and BCL7C. Two transcript variants encoding different isoforms have been found for this gene.
    Molekulargewicht
    25 kDa
Sie sind hier:
Kundenservice